Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: Correlation with transvaginal ultrasonography, computed tomography, and histology

Abstract

PET/CT with 18F-FDG provides additional value to TVUS for the differential diagnosis of benign from malignant pelvic lesions, and to CT for the staging of ovarian cancer patients.

A Case of Meigs’ Syndrome: The 18F-FDG PET/CT Findings

“…These initial results for ovarian cancer show that 18 F-FDG PET had some limitations in distinguishing malignant from benign ovarian tumors. However, in a recent study taking advantage of hybrid PET/CT, Castellucci et al [4] reported higher sensitivity, specificity, and accuracy of 18 F-FDG PET for differentiating between malignant and benign ovarian lesions, and those were 87, 100, and 92%, respectively. The criterion for ovarian malignancy used in the study was a focally increased 18 F-FDG uptake with a maximum standardized uptake value (SUVmax) higher than 3.0 in the ovarian lesion.…”

“…The recently developed [ 18 F] fluorodeoxyglucose ( 18 F-FDG) positron emission tomography/computed tomography (PET/CT) is a promising modality to differentiate a malignant ovarian mass from a benign mass [4]. We report here a case of Meigs' syndrome presenting with bilateral ovarian fibromas and elevated levels of CA-125.…”

Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology

“…FDG-PET/CT scan may be useful for indeterminate lesions. [66][67][68] Most ovarian cancers, including the LCOHs, are diagnosed after pathologic analysis of a biopsy or surgical specimen, which may occur preoperatively, intraoperatively, or postoperatively. If possible, fineneedle aspiration (FNA) should be avoided for diagnosing ovarian cancer in patients with presumed early-stage disease to prevent rupturing the cyst and spilling malignant cells into the peritoneal cavity; however, FNA may be necessary in patients with bulky disease who are not surgical candidates.…”

Lokal- und Ganzkörperdiagnostik weiblicher Beckentumore

“…Zusätzlich konnte durch die Einfüh-rung der 18 F-Fluordesoxyglukose-Positronenemissionstomographie ( 18 F-FDG-PET) sowie der erfolgreichen Implementierung hybrider Bildgebungstechniken wie der PET-CT eine Verbesserung der diagnostischen Genauigkeit beim Nachweis einer Metastasierung oder von Rezidiven gynäkologischer Tumore erreicht werden [2][3][4][5]. Seit Kurzem sind die weltweit ersten kombinierten PET-MRT-Geräte im klinischen Gebrauch.…”